Background: Renal failure is associated with adverse cardiac remodeling and sudden cardiac death. The mechanism leading to enhanced arrhythmogenicity in the cardiorenal syndrome is unclear. The aim of this study was to characterize electrophysiological and tissue alterations correlated with enhanced arrhythmogenicity in two distinct mouse models of renal failure. Methods: Thirty-week-old 129Sv mice received a high-salt diet and deoxycorticosterone acetate (DOCA) for 8 weeks, followed by an additional period of high-salt diet for 27 weeks (DOCA-salt aged model). Adult CD-1 mice were submitted to 5/6-subtotal nephrectomy (SNx) and treated for 11 weeks with a high-salt diet (SNx-salt adult model). Vulnerability to arrhythmia as well as conduction velocities (CVs) of the hearts were determined ex vivo with epicardial mapping. Subsequently, the hearts were characterized for connexin 43 (Cx43) and fibrosis. Results: DOCA-salt and SNx-salt mice developed renal dysfunction characterized by albuminuria. Heart, lung and kidney weights were increased in DOCA-salt mice. Both DOCA-salt and SNx-salt mice were highly susceptible to ventricular arrhythmias. DOCA-salt mice had a significant decrease in both longitudinal and transversal CV in the left ventricle. Histological analysis revealed a significant reduction in Cx43 expression as well as an increase in interstitial fibrosis in both DOCA-salt and SNx-salt mice. Conclusion: DOCA-salt and SNx-salt treatment induced renal dysfunction, which resulted in structural and electrical cardiac remodeling and enhanced arrhythmogenicity. The reduced Cx43 expression and increased fibrosis levels in these hearts are likely candidates for the formation of the arrhythmogenic substrate.

Keywords:
Arrhythmias, Cardiorenal disease, Connexin 43, Fibrosis, Deoxycorticosterone acetate, 5/6-Subtotal nephrectomy
1.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539.
2.
McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL; KEEP Investigators: Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med 2007;167:1122-1129.
3.
Davis TR, Young BA, Eisenberg MS, Rea TD, Copass MK, Cobb LA: Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers. Kidney Int 2008;73:933-939.
4.
Whitman IR, Feldman HI, Deo R: CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol 2012;23:1929-1939.
5.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-2047.
6.
Gaztañaga L, Marchlinski FE, Betensky BP: Mechanisms of cardiac arrhythmias (in English, Spanish). Rev Esp Cardiol (Engl Ed) 2012;65:174-185.
7.
Jansen JA, van Veen TA, de Jong S, van der Nagel R, van Stuijvenberg L, Driessen H, Labzowski R, Oefner CM, Bosch AA, Nguyen TQ, Goldschmeding R, Vos MA, de Bakker JM, van Rijen HV: Reduced Cx43 expression triggers increased fibrosis due to enhanced fibroblast activity. Circ Arrhythm Electrophysiol 2012;5:380-390.
8.
Stein M, Boulaksil M, Jansen JA, Herold E, Noorman M, Joles JA, van Veen TA, Houtman MJ, Engelen MA, Hauer RN, de Bakker JM, van Rijen HV: Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. Am J Physiol Heart Circ Physiol 2010;299:H310-H321.
9.
van Veen TA, van Rijen HV, Wiegerinck RF, Opthof T, Colbert MC, Clement S, de Bakker JM, Jongsma HJ: Remodeling of gap junctions in mouse hearts hypertrophied by forced retinoic acid signaling. J Mol Cell Cardiol 2002;34:1411-1423.
10.
Sweat F, Puchtler H, Rosenthal SI: Sirius red F3Ba as a stain for connective tissue. Arch Pathol 1964;78:69-72.
11.
Ishola DA Jr, van der Giezen DM, Hahnel B, Goldschmeding R, Kriz W, Koomans HA, Joles JA: In mice, proteinuria and renal inflammatory responses to albumin overload are strain-dependent. Nephrol Dial Transplant 2006;21:591-597.
12.
Ma LJ, Fogo AB: Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 2003;64:350-355.
13.
Hartner A, Cordasic N, Klanke B, Veelken R, Hilgers KF: Strain differences in the development of hypertension and glomerular lesions induced by deoxycorticosterone acetate salt in mice. Nephrol Dial Transplant 2003;18:1999-2004.
14.
Esposito C, Dal Canton A: Functional changes in the aging kidney. J Nephrol 2010;23(suppl 15):S41-S45.
15.
Acelajado MC, Oparil S: Hypertension in the elderly. Clin Geriatr Med 2009;25:391-412.
16.
Bolignano D, Mattace-Raso F, Sijbrands EJ, Zoccali C: The aging kidney revisited: a systematic review. Ageing Res Rev 2014;14:65-80.
17.
Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995;269:E657-E662.
18.
Peng H, Carretero OA, Alfie ME, Masura JA, Rhaleb NE: Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene. Hypertension 2001;37:974-980.
19.
Loch D, Hoey A, Morisseau C, Hammock BO, Brown L: Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 2007;47:87-98.
20.
Leelahavanichkul A, Yan Q, Hu X, Eisner C, Huang Y, Chen R, Mizel D, Zhou H, Wright EC, Kopp JB, Schnermann J, Yuen PS, Star RA: Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int 2010;78:1136-1153.
21.
Boulaksil M, Winckels SK, Engelen MA, Stein M, van Veen TA, Jansen JA, Linnenbank AC, Bierhuizen MF, Groenewegen WA, van Oosterhout MF, Kirkels JH, de Jonge N, Varro A, Vos MA, de Bakker JM, van Rijen HV: Heterogeneous Connexin43 distribution in heart failure is associated with dispersed conduction and enhanced susceptibility to ventricular arrhythmias. Eur J Heart Fail 2010;12:913-921.
22.
Kitamura H, Ohnishi Y, Yoshida A, Okajima K, Azumi H, Ishida A, Galeano EJ, Kubo S, Hayashi Y, Itoh H, Yokoyama M: Heterogeneous loss of connexin43 protein in nonischemic dilated cardiomyopathy with ventricular tachycardia. J Cardiovasc Electrophysiol 2002;13:865-870.
23.
Kostin S, Rieger M, Dammer S, Hein S, Richter M, Klövekorn WP, Bauer EP, Schaper J: Gap junction remodeling and altered connexin43 expression in the failing human heart. Mol Cell Biochem 2003;242:135-144.
24.
Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, Nattel S: Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res 2009;105:1213-1222.
25.
Peters NS, Coromilas J, Severs NJ, Wit AL: Disturbed Connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997;95:988-996.
26.
Iravanian S, Sovari AA, Lardin HA, Liu H, Xiao HD, Dolmatova E, Jiao Z, Harris BS, Witham EA, Gourdie RG, Duffy HS, Bernstein KE, Dudley SC Jr: Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43. J Mol Med (Berl) 2011;89:677-687.
27.
Hsueh CH, Chen NX, Lin SF, Chen PS, Gattone VH 2nd, Allen MR, Fishbein MC, Moe SM: Pathogenesis of arrhythmias in a model of CKD. J Am Soc Nephrol 2014;25:2812-2821.
28.
Qu J, Volpicelli FM, Garcia LI, Sandeep N, Zhang J, Marquez-Rosado L, Lampe PD, Fishman GI: Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart. Circ Res 2009;104:365-371.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.